• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Vickers Vantage Corp. I (Amendment)

    1/31/24 5:24:56 PM ET
    $VCKA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $VCKA alert in real time by email
    SC 13D/A 1 d182136dsc13da.htm SC 13D/A SC 13D/A

     

     

    UNITED STATES

    SECURITIES & EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    Scilex Holding Company

    (Name of Issuer)

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)

    Common Stock - 80880W106

    (CUSIP Number)

    Jack Wu

    Sole Manager

    SCLX Stock Acquisition JV LLC

    960 San Antonio Road

    Palo Alto, CA 94303

    (650) 516-4310

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    November 30, 2023

    (Date of Event Which Requires Filing of This Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

     

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 13d-7(b) for other parties to whom copies are to be sent.

     

     

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No.: 80880W106

     

     1.   

     NAME OF REPORTING PERSON

     

     SCLX Stock Acquisition JV LLC

     2.  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☐

     

     3.  

     SEC USE ONLY

     

     4.  

     SOURCE OF FUNDS (SEE INSTRUCTIONS)

     

     SC

     5.  

     CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

     ☐

     6.  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Texas

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7.   

     SOLE VOTING POWER

     

     89,616,299 (1)

        8.  

     SHARED VOTING POWER

     

     0

        9.  

     SOLE DISPOSITIVE POWER

     

     89,616,299 (1)

       10.  

     SHARED DISPOSITIVE POWER

     

     0

    11.   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     89,616,299 (1)

    12.  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    13.  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

     38.2% (2)

    14.  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     OO

     

    (1)

    Comprised of (i) 60,068,585 shares of common stock, par value $0.0001 per share (“Common Stock”), of Scilex Holding Company (the “Issuer”), (ii) 29,057,097 shares of Series A Preferred Stock, par value $0.0001 per share, of the Issuer (“Series A Preferred Stock”) which are entitled to vote, together with the holders of Common Stock, and not separately as a class, on an as converted to Common Stock basis on all matters on which the holders of shares of Common Stock have the right to vote (with the number of votes being determined by dividing the stated value (as determined under the Issuer’s Certificate of Designations of Series A Preferred Stock, filed with the Delaware Secretary of State on November 10, 2022) by $10.00), and (iii) 490,617 shares of Common Stock issuable upon exercise of warrants exercisable within 60 days of the date on which this Schedule 13D has been filed with the Securities and Exchange Commission (“SEC”).

    (2)

    Percent of class beneficially owned is calculated based on 157,905,655 shares of Common Stock outstanding as of November 30, 2023, plus 490,617 shares of Common Stock issuable upon exercise of warrants exercisable within 60 days of the date on which this Schedule 13D has been filed with the SEC. Shares of Series A Preferred Stock are not convertible into shares of Common Stock and therefore the 29,057,097 shares of Series A Preferred Stock held by the Reporting Person are not included in this percentage. The Reporting Person’s aggregate voting power, including shares of Series A Preferred Stock and assuming the exercise of all warrants held by the Reporting Person, is 47.81%.

     

    - 2 -


    Explanatory Note

    This Amendment No. 1 to Schedule 13D (“Amendment No. 1”) amends and supplements the Schedule 13D filed with the Securities and Exchange Commission (“SEC”) on September 29, 2023 (the “Schedule 13D”), relating to the common stock, par value $0.0001 per share (“Common Stock”) of Scilex Holding Company, a Delaware corporation (the “Issuer”). Except as specifically provided herein, this Amendment No. 1 does not modify any of the information previously reported in the Schedule 13D. Capitalized terms used herein without definition shall have the meaning set forth in the Schedule 13D. This Amendment No. 1 was triggered solely due to a change in the number of outstanding shares of Common Stock of the Issuer.

     

    ITEM 5.

    Interest in Securities of the Issuer.

     

    (a)

    See responses to Items 11 and 13 on the cover page.

     

    (b)

    See responses to Items 7, 8, 9 and 10 on the cover page.

     

    (c)

    The Reporting Person has not effected any transactions of Common Stock or Series A Preferred Stock during the 60 days preceding the date of this report.

     

    (d)

    Not applicable.

     

    (e)

    Not applicable.

     

    ITEM 7.

    Material to be Filed as Exhibits.

    Item 7 of the Schedule 13D is hereby amended and supplemented as follows:

     

    Exhibit
    Number
      

    Description

    4    Power of Attorney, dated as of January 31, 2024.

     

    - 3 -


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: January 31, 2024

     

    SCLX STOCK ACQUISITION JV LLC
    By:  

    /s/ Stephen Ma, as Attorney-in-Fact

    Name:   Stephen Ma
    Title:   Attorney-in-Fact for Jack Wu, Sole Manager
    Get the next $VCKA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VCKA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $VCKA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Scilex Holding Company ("Scilex"), a Sorrento Company (nearly 100% or over 99.9% majority-owned subsidiary of Sorrento Therapeutics, Inc.) (Nasdaq: SRNE, "Sorrento"), and Vickers Vantage Corp. I Announce Effectiveness of Registration Statement on Form S-4, Date of Vickers Vantage Extraordinary General Meeting to Approve Proposed Business Combination

      SEC declared Effectiveness of Vickers's registration statement on Form S-4Extraordinary General Meeting of Vickers Vantage Corp. I shareholders to approve the proposed Business Combination is scheduled to be held on November 9, 2022, at 10:00 a.m., Eastern TimePost-closing company will be renamed "Scilex Holding Company" upon closing of the Business Combination, with common stock and warrants expected to trade on the Nasdaq Capital Market under the new ticker symbols "SCLX" and "SCLXW", respectively.Closing of Business Combination can provide up to approximately $100 million of gross cash proceeds in the trust (assuming no redemptions by Vickers Vantage shareholders and before expenses assoc

      10/31/22 9:00:00 AM ET
      $SRNE
      $VCKA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Scilex Holding Company, a Sorrento Company, Announces Pre-Emptive Pay Off of Remaining Balance of its Senior Secured Notes

      PALO ALTO, Calif. and SAN DIEGO, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex"), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that it pre-emptively paid off and eliminated all of its remaining Notes in an aggregate principal amount of $67.7 million for a cash payment of approximately $39.7 million. Scilex is a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))). Scilex Holding Company and Vickers Vantage Corp. I (NASDAQ:VCKA) ("Vickers"), a special purpose acquisi

      9/29/22 9:00:00 AM ET
      $SRNE
      $VCKA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Scilex Holding Company, a Sorrento Company, Announces That the FDA Has Granted Fast Track Designation for SP-103 (Lidocaine Topical System) 5.4%, Next Generation Triple Strength Formulation of ZTlido®, for the Treatment of Acute Low Back Pain (LBP)

      SP-103 receives Fast Track Designation, which makes it eligible for some or all of the following: More frequent meetings or written communication with the FDA to discuss the SP-103 development plan and ensure collection of appropriate data needed to support drug approval.Eligibility for Accelerated Approval or Priority Review, if relevant criteria are met.Rolling Review, which means that Scilex can submit completed sections of its New Drug Application (NDA) for review by the FDA, rather than waiting until every section of the NDA is completed before the entire application can be reviewed. Despite an overall lack of evidence to support their efficacy, opioids continue to be prescribed to trea

      8/30/22 11:21:26 PM ET
      $SRNE
      $VCKA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $VCKA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Vickers Vantage Corp. I (Amendment)

      SC 13D/A - Scilex Holding Co (0001820190) (Subject)

      1/31/24 5:24:56 PM ET
      $VCKA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D filed by Vickers Vantage Corp. I

      SC 13D - Scilex Holding Co (0001820190) (Subject)

      9/29/23 4:15:30 PM ET
      $VCKA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Vickers Vantage Corp. I (Amendment)

      SC 13D/A - Scilex Holding Co (0001820190) (Subject)

      9/26/23 4:49:07 PM ET
      $VCKA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VCKA
    Leadership Updates

    Live Leadership Updates

    See more
    • Scilex Holding Company, a Sorrento Company, announces that the Honorable Tommy G. Thompson has joined the Scilex Board of Directors

      PALO ALTO, Calif., July 05, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex"), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))), a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute and chronic pain, announced today the appointment of the Honorable Tommy G. Thompson, former Secretary of the United States Department of Health and Human Services ("HHS") and former Governor of Wisconsin, to its Board of Directors. Governor Thompson's appointment is effective immediately. Governor Thompson currently serves as the Chief Executive Officer of Thomp

      7/5/22 2:04:42 PM ET
      $SRNE
      $VCKA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Scilex Holding Company a Majority-Owned Subsidiary of Sorrento Therapeutics, Inc., Appoints Highly Accomplished Life Science Executive, Elizabeth Czerepak, as Executive Vice President, Chief Financial Officer (CFO) and Chief Business Officer (CBO)

      SAN DIEGO and PALO ALTO, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex"), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))), who is a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute and chronic pain, announced that Elizabeth Czerepak will join the company as Executive Vice President, Chief Financial Officer and Chief Business Officer, effective May 18, 2022. Ms. Czerepak will be a member of the Scilex and Sorrento Executive Leadership Teams, reporting to Scilex's Chief Executive Officer and President, Jaisim Shah, and Sorr

      4/28/22 9:00:00 AM ET
      $SRNE
      $VCKA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Strengthens Board of Directors with Appointment of Highly Accomplished Pharmaceutical and Biotechnology Executive, Laura Hamill

      PALO ALTO, Calif., April 12, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex"), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))), a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute and chronic pain, announced the appointment of Laura Hamill, an accomplished pharmaceutical and biotechnology executive, to its Board of Directors. Ms. Hamill brings to the Scilex board more than three decades of experience in the biopharma industry, serving most recently as Executive Vice President, Worldwide Commercial Operations at Gilead Sciences, Inc. Prior to

      4/12/22 9:15:46 PM ET
      $SRNE
      $VCKA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $VCKA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Ji Henry

      4 - Scilex Holding Co (0001820190) (Issuer)

      10/5/23 9:35:29 PM ET
      $VCKA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Shah Jaisim

      4 - Scilex Holding Co (0001820190) (Issuer)

      10/5/23 9:28:03 PM ET
      $VCKA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Wu Yue Alexander

      4 - Scilex Holding Co (0001820190) (Issuer)

      10/5/23 9:26:38 PM ET
      $VCKA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VCKA
    SEC Filings

    See more
    • SEC Form 8-K filed by Vickers Vantage Corp. I

      8-K - Scilex Holding Co (0001820190) (Filer)

      2/16/24 1:04:01 PM ET
      $VCKA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by Vickers Vantage Corp. I

      EFFECT - Scilex Holding Co (0001820190) (Filer)

      1/12/24 12:15:11 AM ET
      $VCKA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 424B5 filed by Vickers Vantage Corp. I

      424B5 - Scilex Holding Co (0001820190) (Filer)

      1/11/24 4:53:42 PM ET
      $VCKA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care